NIH Holds Private Meetings on Research Funding
Published Date: 6/12/2026
Notice
Summary
The Center for Scientific Review is holding private meetings to review research grant applications. These closed sessions help decide which science projects get funding, affecting researchers waiting for support. No new costs or timing changes are announced, but these meetings keep the grant review process fair and focused.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
Previous / Next Documents
Previous: 2026-11888, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding who gets research funding. Scientists applying for grants in digestive, kidney, urological, cancer, and immunology fields should note these dates for their funding chances.
Next: 2026-11890, National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting
The National Institute of Biomedical Imaging and Bioengineering is holding a public meeting on September 16, 2026, to discuss important updates and review grant applications. Scientists, researchers, and anyone interested in biomedical imaging and bioengineering can join in person or watch online. This meeting helps decide which projects get funding, so it’s a big deal for innovation and research money.